These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

463 related articles for article (PubMed ID: 30852159)

  • 1. KRAS-mutant non-small cell lung cancer: Converging small molecules and immune checkpoint inhibition.
    Adderley H; Blackhall FH; Lindsay CR
    EBioMedicine; 2019 Mar; 41():711-716. PubMed ID: 30852159
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC).
    Jeanson A; Tomasini P; Souquet-Bressand M; Brandone N; Boucekine M; Grangeon M; Chaleat S; Khobta N; Milia J; Mhanna L; Greillier L; Biemar J; Nanni I; Ouafik L; Garcia S; Mazières J; Barlesi F; Mascaux C
    J Thorac Oncol; 2019 Jun; 14(6):1095-1101. PubMed ID: 30738221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of KRAS mutation in advanced non-small-cell lung cancer treated with immune checkpoint inhibitors: A meta-analysis and review.
    Kim JH; Kim HS; Kim BJ
    Oncotarget; 2017 Jul; 8(29):48248-48252. PubMed ID: 28525386
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Activity of Immune Checkpoint Inhibition in KRAS Mutated Non-small Cell Lung Cancer: A Single Centre Experience.
    Torralvo J; Friedlaender A; Achard V; Addeo A
    Cancer Genomics Proteomics; 2019; 16(6):577-582. PubMed ID: 31659111
    [TBL] [Abstract][Full Text] [Related]  

  • 5. KRAS-Mutant non-small cell lung cancer: From biology to therapy.
    Ferrer I; Zugazagoitia J; Herbertz S; John W; Paz-Ares L; Schmid-Bindert G
    Lung Cancer; 2018 Oct; 124():53-64. PubMed ID: 30268480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. KRAS-G12D mutation drives immune suppression and the primary resistance of anti-PD-1/PD-L1 immunotherapy in non-small cell lung cancer.
    Liu C; Zheng S; Wang Z; Wang S; Wang X; Yang L; Xu H; Cao Z; Feng X; Xue Q; Wang Y; Sun N; He J
    Cancer Commun (Lond); 2022 Sep; 42(9):828-847. PubMed ID: 35811500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of the STK11/KRAS co-mutation on the response to immunotherapy in a real-world pan-cancer cohort.
    Olsen A; Lebedeva A; Nosova P; Nikulin V; Sharova M; Ignatova E; Mileyko V; Ivanov M
    Tumori; 2024 Apr; 110(2):146-152. PubMed ID: 37817679
    [TBL] [Abstract][Full Text] [Related]  

  • 8. KRAS: Reasons for optimism in lung cancer.
    Lindsay CR; Jamal-Hanjani M; Forster M; Blackhall F
    Eur J Cancer; 2018 Aug; 99():20-27. PubMed ID: 29894909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The superior efficacy of anti-PD-1/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicity.
    Liu C; Zheng S; Jin R; Wang X; Wang F; Zang R; Xu H; Lu Z; Huang J; Lei Y; Mao S; Wang Y; Feng X; Sun N; Wang Y; He J
    Cancer Lett; 2020 Feb; 470():95-105. PubMed ID: 31644929
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of Co-occurring Genomic Alterations on Outcomes in Patients with
    Arbour KC; Jordan E; Kim HR; Dienstag J; Yu HA; Sanchez-Vega F; Lito P; Berger M; Solit DB; Hellmann M; Kris MG; Rudin CM; Ni A; Arcila M; Ladanyi M; Riely GJ
    Clin Cancer Res; 2018 Jan; 24(2):334-340. PubMed ID: 29089357
    [No Abstract]   [Full Text] [Related]  

  • 11. If Virchow and Ehrlich Had Dreamt Together: What the Future Holds for
    Köhler J; Jänne PA
    Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33809660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC).
    Salgia R; Pharaon R; Mambetsariev I; Nam A; Sattler M
    Cell Rep Med; 2021 Jan; 2(1):100186. PubMed ID: 33521700
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Response to Checkpoint Inhibition in Non-Small Cell Lung Cancer with Molecular Driver Alterations.
    Kauffmann-Guerrero D; Tufman A; Kahnert K; Bollmann BA; Reu S; Syunyaeva Z; Schneider C; Manapov F; Huber RM; Golpon H
    Oncol Res Treat; 2020; 43(6):289-298. PubMed ID: 32268332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. KRAS oncogene may be another target conquered in non-small cell lung cancer (NSCLC).
    Chen H; Zhao J
    Thorac Cancer; 2020 Dec; 11(12):3425-3435. PubMed ID: 33022831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of immunotherapy in
    Davis AP; Cooper WA; Boyer M; Lee JH; Pavlakis N; Kao SC
    Immunotherapy; 2021 Aug; 13(11):941-952. PubMed ID: 34114474
    [No Abstract]   [Full Text] [Related]  

  • 16. The prevalence and real-world therapeutic analysis of Chinese patients with KRAS-Mutant Non-Small Cell lung cancer.
    Chen H; Huang D; Lin G; Yang X; Zhuo M; Chi Y; Zhai X; Jia B; Wang J; Wang Y; Li J; An T; Wu M; Wang Z; Zhao J
    Cancer Med; 2022 Oct; 11(19):3581-3592. PubMed ID: 35394121
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive value of oncogenic driver subtype, programmed death-1 ligand (PD-L1) score, and smoking status on the efficacy of PD-1/PD-L1 inhibitors in patients with oncogene-driven non-small cell lung cancer.
    Ng TL; Liu Y; Dimou A; Patil T; Aisner DL; Dong Z; Jiang T; Su C; Wu C; Ren S; Zhou C; Camidge DR
    Cancer; 2019 Apr; 125(7):1038-1049. PubMed ID: 30548240
    [TBL] [Abstract][Full Text] [Related]  

  • 18. KRAS-mutation status dependent effect of zoledronic acid in human non-small cell cancer preclinical models.
    Kenessey I; Kói K; Horváth O; Cserepes M; Molnár D; Izsák V; Dobos J; Hegedűs B; Tóvári J; Tímár J
    Oncotarget; 2016 Nov; 7(48):79503-79514. PubMed ID: 27780929
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SHP2 inhibitor specifically suppresses the stemness of KRAS-mutant non-small cell lung cancer cells.
    Jiang L; Xu W; Chen Y; Zhang Y
    Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):3231-3238. PubMed ID: 31373232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel Kras-mutant murine models of non-small cell lung cancer possessing co-occurring oncogenic mutations and increased tumor mutational burden.
    Salehi-Rad R; Li R; Tran LM; Lim RJ; Abascal J; Momcilovic M; Park SJ; Ong SL; Shabihkhani M; Huang ZL; Paul M; Shackelford DB; Krysan K; Liu B; Dubinett SM
    Cancer Immunol Immunother; 2021 Aug; 70(8):2389-2400. PubMed ID: 33507343
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.